Wednesday, April 21, 2021 8:57:37 PM
Wed, April 21, 2021, 1:00 PM
Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its first quarter 2021 financial results on Wednesday, May 5, 2021, before the open of the US financial markets. Clovis’ senior management will host a conference call and live audio webcast at 8:30 a.m. ET to discuss the Company’s results in greater detail.
The conference call will be simultaneously webcast on the Clovis Oncology website www.clovisoncology.com, and a replay of the webcast will be available for 30 days.
Dial-in numbers for the conference call are as follows: US participants 877.698.7048 International participants 647.689.5448, conference ID: 3219208.
About Clovis Oncology
Clovis Oncology, Inc. is a biopharmaceutical company focused on acquiring, developing, and commercializing innovative anti-cancer agents in the US, Europe, and additional international markets. Clovis Oncology targets development programs at specific subsets of cancer populations, and simultaneously develops with partners diagnostic tools intended to direct a compound in development to the population that is most likely to benefit from its use. Clovis Oncology is headquartered in Boulder, Colorado; please visit www.clovisoncology.com for more information, including additional office locations in the US and Europe.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210421005869/en/
Contacts
Clovis Investor Contacts:
Anna Sussman
303.625.5022
asussman@clovisoncology.com
Breanna Burkart
303.625.5023
bburkart@clovisoncology.com
Recent CLVSQ News
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 07/18/2023 04:15:24 AM
- Form 15-12G - Securities registration termination [Section 12(g)] • Edgar (US Regulatory) • 07/11/2023 04:09:55 PM
- Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments • Edgar (US Regulatory) • 07/11/2023 04:05:29 PM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 07/11/2023 03:43:55 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/11/2023 01:37:29 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/30/2023 09:08:05 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM